qfx 
Now, Condire ain’t spreadin’ their bets like a gambler at a county fair. They’re a concentrated sort, holdin’ only 22 different stocks, which is a right peculiar way to run a business if you ask me. But they’ve got $958 million to play with, so who am I to argue? Here’s where they’re layin’ down their money:
A new period thriller arrives on Hulu March 6, 2026, taking place in the 1850s. The film centers on a doctor and a woman with a secret who risk everything to find a life-saving cure for a man who is gravely ill. Featuring Guy Pearce and DeWanda Wise, the movie is a suspenseful story about faith and how far people will go when facing desperation, all set against the backdrop of a difficult time in history. It was produced by Film Bridge International and examines the limits of human strength and the price of hope.
The Women’s Cancer Research Fund’s gala attracted many stars, including Carmen Electra, 53, wearing a revealing ivory gown, Sofia Vergara, 53, in an animal-print dress, and Kerry Washington, 49, in a short, copper dress with silver details. Jennifer Lopez especially turned heads, choosing to skip the red carpet but still making a powerful impression with her outfit.
The sale brought in roughly $347,000, a sum that speaks of prosperity, but also of distance. After the transaction, Okinaka still holds 19,808 shares, valued at approximately $688,000. It’s a comfortable holding, to be sure, but the reduction – a third of her direct stake – is a whisper in the market, a signal that even those closest to the land sometimes prepare for a change in weather.
They bought 2.35 million shares. Two point three five million. In the fourth quarter. It’s just a number, really, until you start thinking about it. And once you start thinking about it, you realize it’s a lot of shares. And then you wonder if they actually looked at the stock price before hitting “buy.”
They just dropped the Q3 numbers, and, frankly, it’s a strange brew. Strong. TOO strong, maybe. Like a double espresso injected directly into the mainframe. Revenue up 22% to $17.2 billion. Analysts expected $16.9? Please. They’re always off. The cloud business is the engine, roaring along at 44% growth, spitting out $8.9 billion. EIGHT POINT NINE BILLION. It’s enough to make a sane man question reality. Adjusted EPS at $1.79, beating expectations? Yeah, okay. Color me… cautiously optimistic. It’s a good sign, but in this business, good signs can be deceptive.
Alphabet, they call it. A grand name, hinting at a whole language of possibility. And in a way, that’s what they’ve built. They’ve woven themselves into the fabric of how we find things, how we talk to each other, how we even think. Google, the heart of it, still hums with the quiet power of search. But it’s no longer just about finding answers; it’s about anticipating the questions. Their Gemini model, a name borrowed from the stars, is learning to read the currents of our curiosity. They hold a share of the world’s gaze, and that is a power not to be underestimated. Like a farmer knowing his land, they understand the seasons of attention.
This investment is, of course, presented as a natural progression. Meta’s algorithms already permeate the very fabric of its social networks – Facebook, Instagram, Messenger, WhatsApp – a subtle yet pervasive control over the flow of information and, consequentially, of thought. Yet, one cannot help but perceive a certain… fragility in this ambition. The stock itself, a barometer of collective faith, has already begun a slow descent – a three percent decline year-to-date – a premonition, perhaps, of difficulties to come.
Both are attempts to cheat entropy, really. To extract something lasting from the chaos of the market. Vanguard’s VYM casts a wide net, owning nearly six hundred companies. A sort of statistical averaging of American industry. Fidelity’s FDVV is more selective. A curated collection. Like choosing which weeds to pull. They both aim for income, but they go about it differently. It’s a difference of philosophy, really. One says, “Diversify, and hope for the best.” The other says, “We have an idea.”
According to a filing with the authorities – a frightfully official document, no doubt – Greenvale has relieved itself of some 1,725,000 shares in Varonis. The value, alas, has dwindled to precisely nothing, a diminution of ninety-nine million dollars from the previous period. A rather dramatic turn of events, wouldn’t you agree? It rather suggests the firm had a sneaking suspicion that things weren’t quite cricket.